General Information of the Compound
| Compound ID |
CP0260468
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
Show/Hide
|
||||||||||||||||||
| Synonyms |
3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester
3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester
AGN 190168
AGN-190168
Avage
Avage (TN)
Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate
Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate
Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
PMID27336223-Compound-10
Suretin
Tazarotene
Tazarotene (JAN/USAN/INN)
Tazarotene [USAN:INN]
Tazaroteno
Tazarotenum
Tazorac
Tazorac (TN)
Tazorac, Avage, Zora, Tazarotene
Tazoral
Zorac
Zorac (TN)
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C21H21NO2S
|
||||||||||||||||||
| Molecular Weight |
351.471
|
||||||||||||||||||
| Canonical SMILES |
CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
Show/Hide
|
||||||||||||||||||
| InChIKey |
OGQICQVSFDPSEI-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
118292-40-3
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT06109, Geminin
Protein ID: PT01475, Retinoic acid receptor alpha
Protein ID: PT01452, Retinoic acid receptor beta
Protein ID: PT01806, Retinoic acid receptor gamma
Clinical Information about the Compound
Drug 1 ( Tazarotene )
| Drug Name | Tazarotene | ||
|---|---|---|---|
| Company | Allergan Pharmaceuticals | ||
| Indication | |||
| Target(s) | |||